1. An early-stage Biogen focused on novel brain disorder treatments.

2. A pre-breakthrough Moderna, but for neuropsychiatric drugs.

3. A niche R&D pharma like Vertex Pharmaceuticals, but specializing in mental health.

• BMB-101: A 5-HT2C receptor agonist in preclinical development for the treatment of Dravet syndrome and other seizure disorders.
• BMB-202: A 5-HT2A/5-HT1A agonist in preclinical development targeting depression, anxiety, and pain disorders.
• BMB-102: A 5-HT2C receptor agonist in preclinical development for the potential treatment of binge eating disorder and substance abuse disorder.

Bright Minds Biosciences (symbol: DRUG) is a pre-clinical and clinical-stage biotechnology company focused on the discovery and development of novel serotonergic therapies for neuropsychiatric disorders. At its current stage of development, the company does not have commercialized products or services generating sales revenue, and therefore does not have major customers in the traditional sense.

The company's primary activities revolve around research and development, aiming to advance its drug candidates through pre-clinical and clinical trials. Because Bright Minds Biosciences is not yet selling products, it does not currently fit the criteria of selling primarily to other companies or primarily to individuals.

In the future, should their drug candidates successfully progress through development and regulatory approval, potential revenue streams and "customers" could emerge:

• If the company pursues licensing or partnership agreements for its intellectual property or drug candidates, other larger pharmaceutical companies would become "customers." Examples of such potential partners, though not current customers, could include companies like Pfizer (PFE), Novartis (NVS), or Johnson & Johnson (JNJ).
• If the company were to commercialize its own approved drugs, the immediate "customers" would be pharmaceutical distributors, wholesalers, or healthcare systems (e.g., hospitals, clinics, pharmacies). Ultimately, the end-users would be individuals (patients) suffering from the targeted neuropsychiatric disorders.

However, as of now, Bright Minds Biosciences does not have identifiable major customers.

Ryan E. S. K. Cheung, Chief Financial Officer
Mr. Cheung is the Chief Financial Officer of Bright Minds Biosciences. He holds a B.Com. and is a Chartered Accountant (CA) and Certified Public Accountant (CPA).

Dr. Jan Torleif Pedersen, Chief Science Officer & Director
Dr. Pedersen is a co-founder of three biotech companies, including Acadia Pharmaceuticals. He has over 25 years of expertise in neuroscience research management. Prior to joining Bright Minds Biosciences, Dr. Pedersen spent 20 years at Lundbeck, a global pharmaceutical company specializing in brain diseases, holding positions of increasing responsibility, including building its neurodegeneration/Alzheimer's disease pipeline and advancing research programs to clinical stages. He is also the founder of Torleif Science ApS, a consultancy company.

Stephen Collins, Chief Medical Officer
Effective immediately, Stephen Collins was named Chief Medical Officer of Bright Minds Biosciences. Before joining the company, Mr. Collins simultaneously served as CEO of Biscayne Neurotherapeutics, and CEO and President of Biscayne Pharmaceuticals.

Dr. Jianmin Duan, Vice President, Pharmacology
Dr. Duan is an experienced pharmaceutical research and development scientist with expertise in drug absorption, distribution, metabolism, excretion, pharmacokinetics, and pharmacology. Prior to his role at Bright Minds Biosciences, Dr. Duan worked as an independent consultant for pharmaceutical and biotechnology companies.

The key risks for Bright Minds Biosciences (DRUG) are primarily related to the inherent challenges of drug development, financial sustainability, and market volatility.

1. Clinical Trial Risk: As an early-stage biotechnology company, Bright Minds Biosciences' success is highly dependent on its drug candidates successfully progressing through and completing clinical trials. The company has limited experience in conducting and completing clinical trials, having only completed one Phase 1 trial to date. There is a significant risk that the company's pipeline could fail in clinical development, which would either delay or terminate product development entirely. Success in preclinical studies or earlier-phase clinical trials does not guarantee similar results in future trials. The long-term prospects of the company are heavily reliant on the successful development and commercialization of its drug candidates.
2. Financial Instability and Need for Capital: Bright Minds Biosciences faces significant profitability challenges, reflected in a negative earnings per share (EPS) and a negative price-to-earnings (P/E) ratio, indicating that current earnings do not support its valuation. The company is currently unprofitable and is not projected to achieve profitability within the next three years. As research and development (R&D) expenses are expected to increase to fund human clinical trials, the company may need to raise additional capital by mid-2026 or potentially earlier, which could lead to shareholder dilution.
3. High Stock Volatility and Potential Overvaluation: The stock of Bright Minds Biosciences has demonstrated extreme volatility, with dramatic price increases and significant swings. Technical indicators have suggested that the stock is often in overbought territory, indicating a potential for price corrections. Analysis suggests a significant disconnect between the current trading price and the company's intrinsic value based on discounted cash flow, indicating that the stock may be overvalued and highly speculative without a robust financial foundation or a clear path to profitability.

The clear emerging threat for Bright Minds Biosciences (DRUG) is the advancement of disease-modifying, gene-targeted therapies for Dravet Syndrome. Bright Minds' lead asset, BMB-101, is a small molecule serotonin receptor agonist intended for symptomatic treatment of Dravet Syndrome. However, companies like Stoke Therapeutics are developing antisense oligonucleotides (ASOs), such as STK-001, which aim to address the genetic root cause of Dravet Syndrome by increasing the expression of the functional SCN1A protein. If these gene-targeted therapies prove highly effective and safe in ongoing clinical trials (some of which are in similar or more advanced phases than BMB-101), they could fundamentally shift the treatment paradigm from symptomatic management to disease modification, significantly diminishing the market opportunity and competitive position of small molecule symptomatic treatments like BMB-101.

Bright Minds Biosciences (DRUG) is a clinical-stage biotechnology company, and as such, its future revenue growth over the next 2-3 years will primarily be driven by key developments in its drug pipeline and strategic collaborations, rather than immediate product sales.

1. Successful Progression and Data Readouts from Clinical Trials for Lead Candidates: A primary driver of future revenue will be the successful advancement of its lead drug candidates through clinical trials and positive data readouts. BMB-101, the company's highly selective 5-HT2C agonist, is currently in Phase 2 clinical studies for rare epilepsies, including Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE), with top-line data from these studies anticipated in early January 2026. Additionally, Bright Minds Biosciences is initiating a Phase 2a study (NOVA) to evaluate BMB-101 for the treatment of Prader-Willi Syndrome (PWS), a rare genetic neurodevelopmental disorder.

2. Expansion of Clinical Pipeline with New Candidates and Indications: The company's strategy includes expanding its pipeline with new drug candidates and exploring additional indications for existing ones. A notable development is the launch of its Prader-Willi Syndrome program and the nomination of BMB-105 as a dedicated new clinical candidate for PWS, aiming to reduce the time to market. Bright Minds Biosciences also has preclinical candidates, such as BMB-201 for treatment-resistant depression and BMB-202 for fast-onset depression, which could represent future revenue streams if they advance into clinical development and eventually commercialization.

3. Strategic Partnerships and Licensing Agreements: Collaborations with other pharmaceutical or biotechnology companies are crucial for clinical-stage firms to fund development, share risks, and potentially accelerate commercialization. Bright Minds Biosciences has already engaged in a collaboration with Firefly Neuroscience to analyze electroencephalogram (EEG) data in the BREAKTHROUGH study for BMB-101, which enhances their clinical trial efforts. Future partnerships or licensing agreements for its drug candidates, especially upon positive clinical data, could provide significant upfront payments, milestone payments, and future royalties, contributing to revenue growth.

Share Issuance

• In February 2021, Bright Minds Biosciences announced an underwritten marketed public offering of units, each consisting of one common share and one-half of one common share purchase warrant.
• In August 2022, the company completed an overnight marketed offering of 2,858,000 units at $1.40 per unit, generating gross proceeds of $4,001,200.
• In late 2024, Bright Minds closed a non-brokered private placement, issuing 1,612,902 common shares at $21.70 per share, which raised $35 million.
• In September 2025, the company announced an "at-the-market" (ATM) equity offering program, authorizing the sale of up to US$100 million in common shares over three years in the United States.

Inbound Investments

• A $35 million non-brokered private placement in late 2024 saw significant participation from institutional investors including Cormorant Asset Management, RA Capital Management, Perceptive Advisors, and Janus Henderson Investors.

Capital Expenditures

• Bright Minds Biosciences' capital expenditures have been negligible for the years for which data is available.
• The net proceeds from various offerings have been primarily allocated towards preclinical and clinical development activities, as well as working capital and general corporate purposes, rather than significant physical capital expenditures.
• The company's primary focus is on research and development for its drug portfolio, as evidenced by summarized R&D expenditures for the fiscal years ended September 30, 2023, 2022, and 2021.